Neuroprotective agents: Cannabinoids

Clinical Immunology

Volumn 142, Issue 1, 2012, Pages 57-67

  Sanchez A J ^a   Garcia Merino A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cannabinoids; Experimental autoimmune encephalomyelitis; Immune modulation; Multiple sclerosis; Neuroprotection

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOL; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; ENDOCANNABINOID; GAMMA INTERFERON; N (3 FURYLMETHYL)ARACHIDONAMIDE; NABIXIMOLS; NEUROPROTECTIVE AGENT; NOLADIN ETHER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RIMONABANT; SR 141716 A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRODHAMINE;

ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; CELL DEATH; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXCITOTOXICITY; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOW DRUG DOSE; LYMPHOCYTE MIGRATION; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SPASTICITY; SYMPTOM; T LYMPHOCYTE;

ANIMALS; CANNABINOIDS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; RECEPTORS, CANNABINOID;

EID: 84856227838     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.02.010     Document Type: Review

References (143)

1. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
2. Bjartmar C., Kinkel R.P., Kidd G., Rudick R.A., Trapp B.D. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001, 57:1248-1252.
3. Jones M.V., Nguyen T.T., DeBoy C.A., Griffin J.W., Whartenby K.A., Kerr D.A., Calabresi P.A. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2008, 199:83-93.
4. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
5. Tsunoda I., Fujinami R.S. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin. Immunopathol. 2002, 24:105-125.
6. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
7. Peterson L.K., Fujinami R.S. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2007, 184:37-44.
8. Charil A., Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J. Neurol. Sci. 2007, 259:7-15.
9. Inglese M., Benedetti B., Filippi M. The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis. J. Neurol. Sci. 2005, 233:15-19.
10. Bar-Joseph A., Berkovitch Y., Adamchik J., Biegon A. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol. 1994, 23:125-135.
11. Lyman W.D., Sonett J.R., Brosnan C.F., Elkin R., Bornstein M.B. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1989, 23:73-81.
12. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994, 28:209-214.
13. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84-87.
14. Berrendero F., Sánchez A., Cabranes A., Puerta C., Ramos J.A., García-Merino A., Fernández-Ruiz J. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 2001, 41:195-202.
15. Arévalo-Martín A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 2003, 23:2511-2516.
16. Croxford J.L., Miller S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. J. Clin. Invest. 2003, 111:1231-1240.
17. Cabranes A., Venderova K., Lago E., Fezza F., Sánchez A., Mestre L., Valenti M., García-Merino A., Ramos J.A., Di Marzo V., Fernandez-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 2005, 20:207-217.
18. Kubajewska I., Constantinescu C.S. Cannabinoids and experimental models of multiple sclerosis. Immunobiology 2010, 215:647-657.
19. Sánchez A.J., González-Pérez P., Galve-Roperh I., García-Merino A. R-(+)-[2, 3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1, 2, 3-de]-1, 4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem. Pharmacol. 2006, 72:1697-1706.
20. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
21. Munro S., Thomas K.L., bu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
22. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le F.G., Casellas P. Cannabinoid-receptor expression in human leukocyte. Eur. J. Biochem. 1993, 214:173-180.
23. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le F.G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232:54-61.
24. Ashton J.C., Friberg D., Darlington C.L., Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. 2006, 396:113-116.
25. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006, 1071:10-23.
26. Molina-Holgado F., Rubio-Araiz A., García-Ovejero D., Williams R.J., Moore J.D., Arévalo-Martin A., Gómez-Torres O., Molina-Holgado E. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur. J. Neurosci. 2007, 25:629-634.
27. Oz M., Zhang L., Ravindran A., Morales M., Lupica C.R. Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J. Pharmacol. Exp. Ther. 2004, 310:1152-1160.
28. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
29. Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006, 8:E298-E306.
30. Baker D., Pryce G., Davies W.L., Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 2006, 27:1-4.
31. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C., Gardner L.S., Griffin G., Jackson H.C., Procter M.J., Rasamison C.M., Tang-Christensen M., Widdowson P.S., Williams G.M., Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006, 3:167-175.
32. Gaoni Y., Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc. 1971, 93:217-224.
33. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 2010, 17:1360-1381.
34. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
35. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50:83-90.
36. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De P.L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8400-8405.
37. Hanus L., bu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U. S. A 2001, 98:3662-3665.
38. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 2002, 301:1020-1024.
39. McKinney M.K., Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 2005, 74:411-432.
40. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14:1347-1356.
41. Hanus L.O., Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr. Med. Chem. 2010, 17:1341-1359.
42. Woelkart K., Salo-Ahen O.M., Bauer R. CB receptor ligands from plants. Curr. Top. Med. Chem. 2008, 8:173-186.
43. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology, XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
44. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 1995, 15:6552-6561.
45. Carracedo A., Lorente M., Egia A., Blazquez C., García S., Giroux V., Malicet C., Villuendas R., Gironella M., Gonzalez-Feria L., Piris M.A., Iovanna J.L., Guzmán M., Velasco G. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006, 9:301-312.
46. Molina-Holgado E., Vela J.M., Arévalo-Martín A., Almazán G., Molina-Holgado F., Borrell J., Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 2002, 22:9742-9753.
47. Massi P., Fuzio D., Vigano D., Sacerdote P., Parolaro D. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur. J. Pharmacol. 2000, 387:343-347.
48. Hasseldam H., Johansen F.F. Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis. Neuroimmunomodulation 2010, 17:252-264.
49. Klein T.W., Cabral G.A. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J. Neuroimmune Pharmacol. 2006, 1:50-64.
50. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010, 215:598-605.
51. Klein T.W., Lane B., Newton C.A., Friedman H. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 2000, 225:1-8.
52. Blanchard D.K., Newton C., Klein T.W., Stewart W.E., Friedman H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int. J. Immunopharmacol. 1986, 8:819-824.
53. Srivastava M.D., Srivastava B.I., Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998, 40:179-185.
54. Watzl B., Scuderi P., Watson R.R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int. J. Immunopharmacol. 1991, 13:1091-1097.
55. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., Roth M.D. Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 2002, 133:124-131.
56. Zheng Z.M., Specter S.C. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. Int. J. Immunopharmacol. 1996, 18:53-68.
57. Klein T.W., Newton C., Widen R., Friedman H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J. Pharmacol. Exp. Ther. 1993, 267:635-640.
58. Shivers S.C., Newton C., Friedman H., Klein T.W. Delta 9-tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci. 1994, 54:1281-1289.
59. Killestein J., Hoogervorst E.L., Reif M., Blauw B., Smits M., Uitdehaag B.M., Nagelkerken L., Polman C.H. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J. Neuroimmunol. 2003, 137:140-143.
60. Sacerdote P., Martucci C., Vaccani A., Bariselli F., Panerai A.E., Colombo A., Parolaro D., Massi P. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J. Neuroimmunol. 2005, 159:97-105.
61. Klein T.W., Kawakami Y., Newton C., Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health 1991, 32:465-477.
62. Malfitano A.M., Matarese G., Pisanti S., Grimaldi C., Laezza C., Bisogno T., Di M., Di Marzo V., Lechler R.I., Bifulco M. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 171:110-119.
63. Pandey R., Mousawy K., Nagarkatti M., Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol. Res. 2009, 60:85-92.
64. Hegde V.L., Hegde S., Cravatt B.F., Hofseth L.J., Nagarkatti M., Nagarkatti P.S. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 2008, 74:20-33.
65. Aranami T., Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 2008, 57:115-120.
66. Cencioni M.T., Chiurchiu V., Catanzaro G., Borsellino G., Bernardi G., Battistini L., Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 2010, 5:e8688.
67. Ross R.A., Brockie H.C., Pertwee R.G. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol. 2000, 401:121-130.
68. Cabral G.A., Toney D.M., Fischer-Stenger K., Harrison M.P., Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci. 1995, 56:2065-2072.
69. López-Cepero M., Friedman M., Klein T., Friedman H. Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. J. Leukoc. Biol. 1986, 39:679-686.
70. Sacerdote P., Massi P., Panerai A.E., Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 2000, 109:155-163.
71. Correa F., Mestre L., Docagne F., Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 2005, 145:441-448.
72. Klegeris A., Bissonnette C.J., McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 2003, 139:775-786.
73. Becher B., Bechmann I., Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J. Mol. Med. 2006, 84:532-543.
74. McCoy K.L., Matveyeva M., Carlisle S.J., Cabral G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 1999, 289:1620-1625.
75. Derocq J.M., Segui M., Marchand J., Le F.G., Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett. 1995, 369:177-182.
76. Klein T.W., Newton C.A., Widen R., Friedman H. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J. Immunopharmacol. 1985, 7:451-466.
77. Kaminski N.E., Koh W.S., Yang K.H., Lee M., Kessler F.K. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem. Pharmacol. 1994, 48:1899-1908.
78. Croxford J.L., Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?. J. Neuroimmunol. 2005, 166:3-18.
79. Schatz A.R., Koh W.S., Kaminski N.E. Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 1993, 26:129-137.
80. Pender M.P., Rist M.J. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 2001, 36:137-144.
81. Do Y., McKallip R.J., Nagarkatti M., Nagarkatti P.S. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 2004, 173:2373-2382.
82. Lu T., Newton C., Perkins I., Friedman H., Klein T.W. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J. Pharmacol. Exp. Ther. 2006, 319:269-276.
83. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
84. Ni X., Geller E.B., Eppihimer M.J., Eisenstein T.K., Adler M.W., Tuma R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler. 2004, 10:158-164.
85. Zhang M., Martin B.R., Adler M.W., Razdan R.J., Kong W., Ganea D., Tuma R.F. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J. Neuroimmune Pharmacol. 2009, 4:249-259.
86. Mestre L., Docagne F., Correa F., Loría F., Hernangomez M., Borrell J., Guaza C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci. 2009, 40:258-266.
87. Matsumoto Y., Ohmori K., Fujiwara M. Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system. J. Neuroimmunol. 1992, 37:23-33.
88. Cabral G.A., Raborn E.S., Griffin L., Dennis J., Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol. 2008, 153:240-251.
89. Aloisi F., Ria F., Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol. Today 2000, 21:141-147.
90. Ortega-Gutierrez S., Molina-Holgado E., Arévalo-Martin A., Correa F., Viso A., Lopez-Rodriguez M.L., Di M., Di Marzo V., Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 2005, 19:1338-1340.
91. Mestre L., Correa F., Arévalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., Di M., Di Marzo V., Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 2005, 92:1327-1339.
92. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
93. Ashton J.C., Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 2007, 5:73-80.
94. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2005, 2:29.
95. Matute C., Alberdi E., Ibarretxe G., Sánchez-Gómez M.V. Excitotoxicity in glial cells. Eur. J. Pharmacol. 2002, 447:239-246.
96. Smith T., Groom A., Zhu B., Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 2000, 6:62-66.
97. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000, 6:67-70.
98. Barkhatova V.P., Zavalishin I.A., Askarova L.S., Shavratskii V.K., Demina E.G. Changes in neurotransmitters in multiple sclerosis. Neurosci. Behav. Physiol. 1998, 28:341-344.
99. Stover J.F., Pleines U.E., Morganti-Kossmann M.C., Kossmann T., Lowitzsch K., Kempski O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur. J. Clin. Invest 1997, 27:1038-1043.
100. Werner P., Pitt D., Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 2001, 50:169-180.
101. Geurts J.J., Wolswijk G., Bo L., van d., Polman C.H., Troost D., Aronica E. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003, 126:1755-1766.
102. Srinivasan R., Sailasuta N., Hurd R., Nelson S., Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain 2005, 128:1016-1025.
103. van der S.M., Veldhuis W.B., Bar P.R., Veldink G.A., Vliegenthart J.F., Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 2001, 21:6475-6479.
104. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der S., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di M., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
105. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., Ledent C., Petzold A., Thompson A.J., Giovannoni G., Cuzner M.L., Baker D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202.
106. Khaspekov L.G., Brenz Verca M.S., Frumkina L.E., Hermann H., Marsicano G., Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. 2004, 19:1691-1698.
107. Docagne F., Muneton V., Clemente D., Ali C., Loria F., Correa F., Hernangomez M., Mestre L., Vivien D., Guaza C. Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol. Cell. Neurosci. 2007, 34:551-561.
108. Achiron A., Miron S., Lavie V., Margalit R., Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. 2000, 102:26-31.
109. Loria F., Petrosino S., Hernangomez M., Mestre L., Spagnolo A., Correa F., Di M., Di Marzo V., Docagne F., Guaza C. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol. Dis. 2010, 37:166-176.
110. Witting A., Chen L., Cudaback E., Straiker A., Walter L., Rickman B., Moller T., Brosnan C., Stella N. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6362-6367.
111. Shen M., Thayer S.A. The cannabinoid agonist Win, 55, 212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 1998, 783:77-84.
112. Smith K.J., Kapoor R., Felts P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999, 9:69-92.
113. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261-268.
114. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidant. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8268-8273.
115. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 2002, 80:448-456.
116. Compston A. Remyelination of the central nervous system. Mult. Scler. 1996, 1:388-392.
117. Mechoulam R., Lichtman A.H. Neuroscience. Stout guards of the central nervous system. Science 2003, 302:65-67.
118. Jackson S.J., Pryce G., Diemel L.T., Cuzner M.L., Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005, 134:261-268.
119. Maresz K., Pryce G., Ponomarev E.D., Marsicano G., Croxford J.L., Shriver L.P., Ledent C., Cheng X., Carrier E.J., Mann M.K., Giovannoni G., Pertwee R.G., Yamamura T., Buckley N.E., Hillard C.J., Lutz B., Baker D., Dittel B.N. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 2007, 13:492-497.
120. Croxford J.L., Pryce G., Jackson S.J., Ledent C., Giovannoni G., Pertwee R.G., Yamamura T., Baker D. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol. 2008, 193:120-129.
121. Benito C., Tolón R.M., Pazos M.R., Nuñez E., Castillo A.I., Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol. 2008, 153:277-285.
122. Fernández-Ruiz J., Pazos M.R., García-Arencibia M., Sagredo O., Ramos J.A. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell. Endocrinol. 2008, 286:S91-S96.
123. Davoust N., Vuaillat C., Cavillon G., Domenget C., Hatterer E., Bernard A., Dumontel C., Jurdic P., Malcus C., Confavreux C., Belin M.F., Nataf S. Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia. FASEB J. 2006, 20:2081-2092.
124. Palazuelos J., Davoust N., Julien B., Hatterer E., Aguado T., Mechoulam R., Benito C., Romero J., Silva A., Guzmán M., Nataf S., Galve-Roperh I. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 2008, 283:13320-13329.
125. Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzman M., Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006, 20:2405-2407.
126. Dittel B.N. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br. J. Pharmacol. 2008, 153:271-276.
127. Bittner S., Meuth S.G., Gobel K., Melzer N., Herrmann A.M., Simon O.J., Weishaupt A., Budde T., Bayliss D.A., Bendszus M., Wiendl H. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 2009, 132:2501-2516.
128. Sun Y., Alexander S.P., Garle M.J., Gibson C.L., Hewitt K., Murphy S.P., Kendall D.A., Bennett A.J. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br. J. Pharmacol. 2007, 152:734-743.
129. Collin C., Ehler E., Waberzinek G., Alsindi Z., Davies P., Powell K., Notcutt W., O'Leary C., Ratcliffe S., Novakova I., Zapletalova O., Pikova J., Ambler Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 2010, 32:451-459.
130. Killestein J., Hoogervorst E.L., Reif M., Kalkers N.F., Van Loenen A.C., Staats P.G., Gorter R.W., Uitdehaag B.M., Polman C.H. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58:1404-1407.
131. Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-819.
132. Russo E.B. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2003, 60:729-730.
133. Svendsen K.B., Jensen T.S., Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004, 329:253.
134. Vaney C., Heinzel-Gutenbrunner M., Jobin P., Tschopp F., Gattlen B., Hagen U., Schnelle M., Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 2004, 10:417-424.
135. Wade D.T., Makela P., Robson P., House H., Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 2004, 10:434-441.
136. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526.
137. Benito C., Romero J.P., Tolón R.M., Clemente D., Docagne F., Hillard C.J., Guaza C., Romero J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 2007, 27:2396-2402.
138. Centonze D., Bari M., Rossi S., Prosperetti C., Furlan R., Fezza F., De Chiara V., Battistini L., Bernardi G., Bernardini S., Martino G., Maccarrone M. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007, 130:2543-2553.
139. Jean-Gilles L., Feng S., Tench C.R., Chapman V., Kendall D.A., Barrett D.A., Constantinescu C.S. Plasma endocannabinoid levels in multiple sclerosis. J. Neurol. Sci. 2009, 287(1-2):212-215.
140. Cernak I., Vink R., Natale J., Stoica B., Lea P.M., Movsesyan V., Ahmed F., Knoblach S.M., Fricke S.T., Faden A.I. The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J. Cereb. Blood Flow Metab. 2004, 24:564-578.
141. Fowler C.J., Rojo M.L., Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?. Exp. Neurol. 2010, 224:37-47.
142. Papathanasopoulos P., Messinis L., Lyros E., Kastellakis A., Panagis G. Multiple sclerosis, cannabinoids, and cognition. J. Neuropsychiatry Clin. Neurosci. 2008, 20:36-51.
143. Webb M., Luo L., Ma J.Y., Tham C.S. Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci. Lett. 2008, 439:106-110.